Patent intelligence · US
US 10683503
Antisense oligomers for treatment of conditions and diseases
Antisense oligomers for treatment of conditions and diseases
Patent details — US 10683503
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 16, 2020
- Expiration
- Jun 11, 2040
- Applicant
- STOKE THERAPEUTICS, INC.
- Claims
- 62
- CPC classes
- A61K, A61K9/0019, A61K9/0085, A61P
Quick answer
US 10683503 (Antisense oligomers for treatment of conditions and diseases) is held by STOKE THERAPEUTICS, INC.. Status: granted. Granted Jun 16, 2020. Expires Jun 11, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- STOKE THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 62
- CPC classes
- A61K, A61K9/0019, A61K9/0085, A61P, A61P25/00, A61P25/12
More from STOKE THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12338437
OPA1 antisense oligomers for treatment of conditions and diseases
granted -
US 12060558
Methods and compositions for treatment of cholesteryl ester storage disease
granted -
US 11873490
Antisense oligomers for treatment of conditions and diseases
granted -
US 11814622
OPA1 antisense oligomers for treatment of conditions and diseases
granted -
US 11096956
Antisense oligomers and uses thereof
granted -
US 11083745
Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome
granted -
US 10913947
Antisense oligomers for treatment of conditions and diseases
granted
Frequently asked questions
What is US patent 10683503?
US 10683503 (Antisense oligomers for treatment of conditions and diseases) is held by STOKE THERAPEUTICS, INC.. Status: granted. Granted Jun 16, 2020. Expires Jun 11, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10683503?
STOKE THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 10683503 expire?
Our index shows an expiration date of Jun 11, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.